|
Age [years, median (range)] |
62 (28 - 84) |
65 (39 - 79) |
60 (28 - 81) |
62 (20 - 79) |
|
Gender (male/female) |
154/105 |
69/61 |
83/49 |
162/111 |
|
Tumour location (head/body, tail) |
153/106 |
72/58 |
59/73 |
203/70 |
|
Serum CA19-9 [U/mL, median (range)] |
169.4 (5.1 - 17690.0) |
341.3 (5.6 - 21430.0) |
891.1 (6.2 - 25280.0) |
146.3 (5.4 - 20740.0) |
|
Serum CA125 [U/mL, median (range)] |
17.3 (2.2 - 539.7) |
27.0 (4.0 - 786.2) |
72.3 (5.2 - 12751.0) |
24.2 (2.4 - 666.5) |
|
Serum CEA [ng/mL, median (range)] |
3.5 (0.4 - 406.9) |
4.7 (0.8 - 444.1) |
6.9 (0.7 - 951.0) |
2.7 (0.3 - 256.0) |
|
Serum CA242 [U/mL, median (range)] |
30.0 (0.1 - 238.1) |
39.4 (0.1 - 216.0) |
115.9 (0.1 - 316.0) |
24.8 (0.1 - 298.0) |
|
Serum CA72-4 [U/mL, median (range)] |
2.3 (0.7 - 1190.8) |
3.0 (0.8 - 148.8) |
5.0 (0.7 - 300.0) |
3.0 (0.8 - 253.8) |
|
Serum CA50 [U/mL, median (range)] |
35.3 (0.6 - 1120.9) |
20.4 (1.5 - 1047.7) |
23.5 (0.8 - 1126.0) |
28.7 (0.4 - 380.0) |
|
Serum CA153 [U/mL, median (range)] |
12.5 (4.4 - 230.1) |
13.6 (4.1 - 163.6) |
16.7 (4.7 - 300.0) |
19.3 (5.2 - 57.4) |
|
Serum AFP [ng/mL, median (range)] |
3.0 (0.7 - 3000.0) |
2.9 (0.9 - 58.2) |
3.0 (0.7 - 68.8) |
3.0 (0.9 - 313.0) |
|
TNM stage (I/IIA/IIB/III/IV) |
48/78/133/0/0 |
0/0/0/130/0 |
0/0/0/0/132 |
54/63/156/0/0 |
|
Tumour size (cm, mean ± SD) |
4.65 ± 1.75 |
/ |
/ |
4.49 ± 1.38 |
|
Lymph node metastasis (yes/no) |
133/126 |
/ |
/ |
156/117 |
|
Differentiation (well, moderate/poor) |
167/92 |
/ |
/ |
177/96 |
|
Neural invasion (yes/no) |
218/41 |
/ |
/ |
185/88 |
|
Microvascular invasion (yes/no) |
64/195 |
/ |
/ |
83/190 |
|
Chemotherapy (yes/no) |
210/49 |
114/16 |
122/10 |
186/87 |
|
Chemoradiotherapy (yes/no) |
66/193 |
29/101 |
16/116 |
39/234 |
